The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Open accessAbstract
BACKGROUND: Progressive multiple sclerosis (MS) is characterized by compartmentalized smoldering neuroinflammation caused by the proliferation of immune cells residing in the central nervous system (CNS), including B cells. Although inflammatory activity can be prevented by immunomodulatory therapies during early disease, such therapies typically fail to halt disease progression. CD19 chimeric antigen receptor (CAR)-T cell therapies have revolutionized the field of hematologic malignancies. Although generally considered efficacious, serious adverse events associated with CAR-T cell therapies such as immune effector cell-associated neurotoxicity syndrome (ICANS) have been observed. Successful use of CD19 CAR-T cells in rheumatic diseases like systemic lupus erythematosus and neuroimmunological diseases like myasthenia gravis have recently been observed, suggesting possible application in other autoimmune diseases. METHODS: Here, we report the first individual treatment with a fully human CD19 CAR-T cell therapy (KYV-101) in two patients with progressive MS. FINDINGS: CD19 CAR-T cell administration resulted in acceptable safety profiles for both patients. No ICANS was observed despite detection of CD19 CAR-T cells in the cerebrospinal fluid. In case 1, intrathecal antibody production in the cerebrospinal fluid decreased notably after CAR-T cell infusion and was sustained through day 64. CONCLUSIONS: target cells in the CNS. Larger clinical studies assessing CD19 CAR-T cells in MS are warranted. FUNDING: Both individual treatments as well the generated data were not based on external funding.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Immunopathology of multiple sclerosis
Dendrou, C. A., Fugger, L., & Friese, M. A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3871 · Cited by 2,215
Self-citationThe immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380
Self-citation
Cited by
Neuroinflammation across neurological diseases
Shi, F.-D., & Yong, V. W. (2025) · Science · doi:10.1126/science.adx0043 · Cited by 274
Metadata
- Authors
- Fischbach, F., Richter, J., Pfeffer, L. K., Fehse, B., Berger, S. C., Reinhardt, S., Kuhle, J., Badbaran, A., Rathje, K., Gagelmann, N., Borie, D., Seibel, J., Ayuk, F., Friese, M. A., Heesen, C., & Kröger, N.
- Venue
- Med
- Publisher
- Elsevier BV
- Published
- 2024-06
- Volume
- 5
- Issue
- 6
- Pages
- 550-558.e2
- ISSN
- 2666-6340 (ISSN-L)
- OpenAlex
- W4393321268
- Cited by
- 192
- References
- 3
- FWCI
- 29.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. https://app.cochat.ai/papers/10.1016/j.medj.2024.03.002
- The paper
- Fischbach, F., Richter, J., Pfeffer, L. K., Fehse, B., Berger, S. C., Reinhardt, S., Kuhle, J., Badbaran, A., Rathje, K., Gagelmann, N., Borie, D., Seibel, J., Ayuk, F., Friese, M. A., Heesen, C., & Kröger, N. (2024). CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med. https://doi.org/10.1016/j.medj.2024.03.002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.